New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-t... - 26 February 2021 00:25

DARMSTADT, Germany, Feb. 26, 2021 /PRNewswire-AsiaNet / -- MAGNIFY-MS retrospective analysis demonstrates patients develop protective antibody levels for at least six months following seasonal influenza and varicella zoster vaccines, irrespective of vaccine timing relative to MAVENCLAD dosing Initial f...

  Polyplastics Expands DURACON (R) POM PM Series with New High-f... - 25 February 2021 18:00

TOKYO, Feb. 25, 2021 /Kyodo JBN-AsiaNet/-- The Polyplastics Group is expanding its DURACON (R) polyoxymethylene (POM) PM series portfolio with the development of a new high-flow grade for drug contact and delivery applications for the medical and healthcare market. The new grade, DURACON P...

  New FDI World Dental Federation global survey reveals that two... - 25 February 2021 10:01

GENEVA, Feb. 24, 2021 /PRNewswire-AsiaNet/ -- -- Survey also shows that half of the responding countries have agreed to include dentists in their priority vaccination groups FDI World Dental Federation today [ http://www.fdiworlddental.org/vaccines ] called for more countries to enable...

  Occlutech announces Completion of Patient Enrolment in Pilot S... - 24 February 2021 23:58

SCHAFFHAUSEN, Switzerland, February 24, 2021, /PRNewswire-AsiaNet/-- Occlutech, a privately-held company, announced today the completion of patient enrolment in its pilot study to assess safety and efficacy of the novel Atrial Flow Regulator (AFR) in heart failure (HF) patients (PRELIEVE trial). PRELIEVE is a pr...

  INOVIO and QIAGEN expand collaboration to develop next generat... - 24 February 2021 17:45

PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, Feb. 24, 2021 /PRNewswire- -- Liquid biopsy-based precision test guides patient selection and offers potential for cost-effective, non-invasive alternative to surgical removal of cervical lesions -- QIAGEN's bioinformatic expertise raises predictive bioma...

  US Court Grants MGI's Motion to Amend in Suit Against Illumina - 24 February 2021 07:36

SAN FRANCISCO, Feb. 24, 2021 /PRNewswire-Asianet/ -- A judge in the U.S. District Court for the Northern District of California has granted MGI's motion for leave to amend to add a new inequitable conduct defense of patent infringement lawsuit that Illumina filed against MGI in February 2020 (Case N...

  RedHill Biopharma Announces Planned Expansion of Opaganib Glob... - 24 February 2021 00:33

TEL AVIV, Israel and RALEIGH, NC, Feb. 23, 2021 /PRNewswire-AsiaNet / -- Following review of data from the U.S. Phase 2 study by the FDA, RedHill plans to expand the global Phase 2/3 study of orally-administered opaganib for severe COVID-19 to the U.S. The study has enrolled over 50% of the targeted 464 patients gl...

  INOVIO Announces First Subject Dosed in Phase 1B Clinical Tria... - 24 February 2021 00:00

PLYMOUTH MEETING, Pa., Feb. 23, 2021 /PRNewswire-AsiaNet/ -- -- Phase 1B clinical trial is first study for Lassa fever conducted in Africa -- Goal is for vaccine to be available for emergency use as stockpile product following Phase 2 -- Progress on INO-4500 reflects INOVIO's focus on an...

  Surgical Wait Times Technology Now Available in Australia and ... - 23 February 2021 08:00

SYDNEY, Feb. 23, 2021 /PRNewswire-AsiaNet/ -- -- Fastest Growing Canadian Health Technology Company Expands Into ANZ Wait times in both Australia and New Zealand are too long and how patients are admitted for surgery hasn't changed in decades. Unlike elsewhere, the process is unnecessarily...

  Los Angeles Lakers Name Hyperice Official Recovery Technology ... - 23 February 2021 01:00

EL SEGUNDO, Calif. and IRVINE, Calif., Feb. 23, 2021 /PRNewswire-AsiaNet/ -- -- First NBA Team Deal Returns the Recovery Technology Leader to its Southern California Roots The Los Angeles Lakers and Hyperice( https://c212.net/c/link/?t=0&l=en&o=3073861-1&h=2252051198&u=https%3A%2F%2Fhyperice.com%2F&a=Hyperice ) announce...